[Home ] [Archive]    
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 13, Issue 2 (jun & july 2008) ::
pajoohande 2008, 13(2): 81-88 Back to browse issues page
The Effect of Hudroxyurea on Extramedullary Hematopoietic Masses in Patients with
Mojtahedzadeh F * , Kosaryan M , Kowsarian SAH , Karami H
, dr_mojtahedzade@yahoo.com
Abstract:   (34921 Views)
Background: Since the need for transfusions in thalassemia intermediate (TI) patients is limited into some rare occasions they are almost always referred complaining of problems due to chronic anemia, bone marrow hyper-functioning (such as gall stones, osteoporosis) and also extramedullary hematopoiesis masses (EMH). Different treatment modalities have been reported for managing the latter complication. We carried out this study to evaluating the effects of Hydroxyurea in reducing the size of such masses. Materials and Methods: The study was clinical trial comparing before and after characteristics of the patients referred to the Talassemia Research center from 2003 to 2006. Presentation of all was pain, weakness, paresthesia of legs and paraparesia/paraplegia. Diagnosis of EHM was confirmed by Spinal MRI (a 1.5 Tesla, Toshiba machine). Hydroxiurea (Syrea, Medac, Germany) was administered 10-20 mg/kg/day. CBC, Urea, Creatinin were checked monthly. A Neurologist was observing the progression of patients. The second MRI was performed 3-6 months later. Another radiologist unaware of the sequence of imaging reported the changes of EHM during the period. Paired-t test and McNemar test were applied to compare the results. P< 0.05 was considered as statistically significant. Results: Eight patients (7 males and 1 female) were enrolled in our study. Their age ranged from 26-44 years old. None had undergone transfusion, nor had they used pain killers. Neurologic symptoms were initiated from one week to a couple of months prior to their admission. They had administered Hydroxyurea in recommended dosage. The follow up takes 0.7 - 4.7 years. All subjects improved within 2 weeks, whereas none of them needed surgical procedures and radiotherapy. Both the MCV and NRBC changes were significant (P<0.02). No considerable side-effects were noticed within the follow up period. Conclusion: HU is proved to be both effective and safe in treatment of EHM amongst patients with thalassemia intermediate who develop neurological symptoms. We suggest hydroxyurea as a "prophylactic agent" for several complications of TI.
Keywords: Hudroxyurea, Extramedullary hematopoiesis, beta-thalassemia intermediate, MRI
Full-Text [PDF 214 kb]   (2915 Downloads)    
Type of Study: Original | Subject: Medicine
Received: 2017 | Accepted: 2017 | Published: 2017
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mojtahedzadeh F, Kosaryan M, Kowsarian SAH, Karami H. The Effect of Hudroxyurea on Extramedullary Hematopoietic Masses in Patients with . pajoohande 2008; 13 (2) :81-88
URL: http://pajoohande.sbmu.ac.ir/article-1-643-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 2 (jun & july 2008) Back to browse issues page
Persian site map - English site map - Created in 0.05 seconds with 36 queries by YEKTAWEB 4645